Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04JTD
|
|||
| Former ID |
DCL000205
|
|||
| Drug Name |
PX-12
|
|||
| Synonyms |
PX12, PX 12, IV-2
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Biomira
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C7H12N2S2
|
|||
| Canonical SMILES |
CCC(C)SSC1=NC=CN1
|
|||
| InChI |
1S/C7H12N2S2/c1-3-6(2)10-11-7-8-4-5-9-7/h4-6H,3H2,1-2H3,(H,8,9)
|
|||
| InChIKey |
BPBPYQWMFCTCNG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 141400-58-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9374284, 15219811, 30422463, 57399846, 79245557, 103106749, 103564705, 113468605, 117402020, 123121574, 126460084, 135142363, 140114675, 162249061, 162310065, 162790932, 164154946, 164210775, 170364272, 174006855, 175427007, 177748841, 204361145, 210274949, 210280587, 215774935, 223392225, 223435396, 227058245, 243264143, 252156900, 252161718, 252475622
|
|||
| ChEBI ID |
CHEBI:94291
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thioredoxin (TXN) | Target Info | Inhibitor | [2], [3], [4] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| Panther Pathway | Hypoxia response via HIF activation | |||
| Oxidative stress response | ||||
| Pathwhiz Pathway | Purine Metabolism | |||
| Pathway Interaction Database | p38 MAPK signaling pathway | |||
| Signaling events mediated by PTP1B | ||||
| TNF receptor signaling pathway | ||||
| Reactome | Oxidative Stress Induced Senescence | |||
| Detoxification of Reactive Oxygen Species | ||||
| TP53 Regulates Metabolic Genes | ||||
| The NLRP3 inflammasome | ||||
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| Detoxification of Reactive Oxygen Species | ||||
| Human Complement System | ||||
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | ||||
| TNF alpha Signaling Pathway | ||||
| Metabolism of nucleotides | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med. 2006 Feb;147(2):83-90. | |||
| REF 2 | 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Mol Cancer Ther. 2008 Jan;7(1):143-51. | |||
| REF 3 | Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):359-73. | |||
| REF 4 | A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2109-14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.